Heron Therapeutics (HRTX) Other Working Capital Changes (2010 - 2026)

Heron Therapeutics has reported Other Working Capital Changes for 17 years, with the latest figure at -$1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Working Capital Changes fell 113.04% year-over-year to -$1.1 million; the trailing twelve-month figure through Mar 2026 stood at -$10.6 million (down 157.92% YoY), and the FY2025 full-year result was -$878000.0, down 108.84% from the prior year.
• Other Working Capital Changes for Q1 2026 stood at -$1.1 million, up from -$5.4 million in the prior quarter.
• The five-year high for Other Working Capital Changes was $8.6 million in Q1 2025, with the low at -$9.5 million in Q2 2023.
• Historically, Other Working Capital Changes has averaged -$500529.4 across 5 years, with a median of -$289000.0 in 2024.
• The largest YoY upside for Other Working Capital Changes was 3775.68% in 2025 against a maximum downside of 3118.69% in 2025.
• Heron Therapeutics' Other Working Capital Changes stood at $4.7 million in 2022, then plunged by 203.58% to -$4.9 million in 2023, then jumped by 226.06% to $6.2 million in 2024, then plunged by 188.15% to -$5.4 million in 2025, then surged by 79.33% to -$1.1 million in 2026.
• The last three Other Working Capital Changes figures came in at -$1.1 million (Q1 2026), -$5.4 million (Q4 2025), and $5.2 million (Q3 2025), per Business Quant data.